Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGFR | P43088 | 6/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25234129 | 1.00 | CFTR (0.36) | CFTRKDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL30007363 | 0.94 | CFTR (0.38) | CFTRMAPTPTGFRGABRA5KMT2A | |
| SCHEMBL23958764 | 0.94 | CFTR (0.38) | CFTRMAPTPTGFRGABRA5KMT2A | |
| SCHEMBL25687239 | 0.94 | CFTR (0.38) | CFTRMAPTPTGFRGABRA5KMT2A | |
| SCHEMBL23958750 | 0.91 | CFTR (0.36) | CFTRKDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL30007224 | 0.91 | CFTR (0.36) | CFTRKDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL23958781 | 0.91 | CFTR (0.36) | CFTRKDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL30006889 | 0.89 | CFTR (0.36) | CFTRKDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL25687212 | 0.89 | CFTR (0.36) | CFTRKDM4EALDH1A1HTTNPSR1 | |
| SCHEMBL23958734 | 0.86 | CFTR (0.38) | CFTRKDM4EALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885KDM4E 3733/4885ALDH1A1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.